{"title":"2021-2022年血液恶性肿瘤药物更新。","authors":"Jenni Tobin","doi":"10.6004/jadpro.2023.14.3.10","DOIUrl":null,"url":null,"abstract":"<p><p>During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"232-235"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/9c/jadpro-14-232.PMC10184846.pdf","citationCount":"0","resultStr":"{\"title\":\"2021-2022 Drug Updates in Hematologic Malignancies.\",\"authors\":\"Jenni Tobin\",\"doi\":\"10.6004/jadpro.2023.14.3.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.</p>\",\"PeriodicalId\":17176,\"journal\":{\"name\":\"Journal of the Advanced Practitioner in Oncology\",\"volume\":\"14 3\",\"pages\":\"232-235\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/9c/jadpro-14-232.PMC10184846.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Advanced Practitioner in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.3.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.3.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在JADPRO Live 2022期间，Jenni Tobin, PharmD回顾了从2021年底到2022年底批准的新批准的血液恶性肿瘤(包括多发性骨髓瘤、淋巴瘤和急性白血病)治疗的适应症。Tobin博士讨论了它们独特的作用机制，给药，以及如何监测和管理与这些新疗法相关的副作用。
2021-2022 Drug Updates in Hematologic Malignancies.
During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
